41 results about "Mycobacterial cell" patented technology

Attenuated strains of Mycobacterium, particularly species of the tuberculosis complex, have the mycobacterial cell entry (mce) gene functionally disabled. The gene may be disabled by an insertion into the gene which disrupts the mycobacterial cell entry function thereof of a selectable marker which is used for screen for homologous recombinants in which a double cross-over event has been effected. The attenuated strains may be used in the immunization of hosts against Mycobacterium disease.

The invention relates to a carbohydrate chip for quickly diagnosing tuberculosis, which comprises a solid-phase carrier. The carbohydrate chip is characterized by further comprising a mycobacterium tuberculosis lipopolysaccharides antigen probe which is fixed on the solid-phase carrier through oximation reaction. The invention also relates to a preparation method of the carbohydrate chip and a tuberculosis diagnostic kit adopting the carbohydrate chip. The preparation method comprises the following steps: separating, extracting and purifying lipopolysaccharides in a mycobacterium tuberculosis cell wall; fixing LAM (lipoarabinomannan) and LM (lipomannan) probes in the solid-phase carrier, such as a nitrocellulose membrane or porous plate, and the like, by utilizing a method of oximation reaction, thereby obtaining the carbohydrate chip; and judging if the mycobacterium tuberculosis is infected, by bonding the carbohydrate chip with a corresponding antibody in blood serum and performing enzyme linked color-developing reaction. A cell wall lipopolysaccharides antigen with species specificity adopted by the carbohydrate chip only can be combined with a specific tuberculosis antibody, so that the detecting specificity and sensitivity of the tuberculosis are greatly increased.

Attenuated strains of Mycobacterium, particularly species of the tuberculosis complex, have the mycobacterial cell entry (mce) gene functionally disabled. The gene may be disabled by an insertion into the gene which disrupts the mycobacterial cell entry function thereof of a selectable marker which is used for screen for homologous recombinants in which a double cross-over event has been effected. The attenuated strains may be used in the immunization of hosts against Mycobacterium disease.

A recombinant bacterial cell strain is disclosed. It comprises: a) a first vector comprising a fusion transgene encoding Ag85B-CFP10 fusion protein, the fusion transgene being operably linked to a promoter effective for expression of the Ag85B-CFP10 fusion protein; and b) a second vector comprising a transgene encoding interleukin-12 (IL-12), the transgene being operably linked to a promoter effective for expression of the IL-12 protein. A method of inhibiting intracellular growth of Mycobacterium in a subject is also disclosed.

The present invention relates to oxazolidinone compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of an oxazolidinone of the invention and / or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and / or salt.

The present invention provides a diagnostic test method for detecting a tendency to rifampin resistance caused by mutations in a rpoB gene of M. tuberculosis, comprising the steps of (i) extracting genomic DNA from a biological sample containing M. tuberculosis cells; (ii) amplifying from the extracted genomic DNA the rpoB gene coding sequence or at least one distinct fragment thereof containing nucleotides encoding at least one test amino acid of the group consisting of amino acid numbers 511, 512, 513, 514, 515, 516, 517, 518, 522, 526, 529, 531, 533 to produce fluorescently labeled amplification product; (iii) contacting said fluorescently labeled amplification product with a first control array of oligonucleotide probes having DNA sequences specific to the wildtype M. tuberculosis rpoB gene coding sequence, including the nucleotides encoding the at least one test amino acid, and with a second test array of oligonucleotide probes having DNA sequences specific to the M. tuberculosis rpoB gene coding sequence, including nucleotides encoding mutations in the at least one test amino acid, wherein at least 3 mutations of the rpoB gene are probed for by the second test array of oligonucleotide probes; detecting any fluorescent hybridization signal of said purified fluorescently labeled amplification product which hybridized with the first and second arrays of oligonucleotide probes; (iv) correlating said detected hybridization with a tendency to rifampin resistance; and (v) correlating the detected hybridization to a tendency to rifampcin resistance and MDR.

Novel compounds belonging to the class of oxazolidinones possessing potent antimycobacterial properties especially useful in the treatment of acid fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium-intracellular complex, M. fortuitum and M. kansai. The compound and its pharmaceutically acceptable salts act as antibacterial agents. Also mentioned is a method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial conditions such as Mycobacterium tuberculosis, drug resistant Mycobacterium tuberculosis, Mycobacterium avium-intracellular complex, M. fortuitum and M. kansai., including administering an antimycobacterially effective amount of the compound and / or pharmaceutically acceptable salts. There is also mentioned a process for the manufacture of the compound or its pharmaceutically acceptable salts.

The present invention relates to oxazolidinone compounds of Formula (I):and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of an oxazolidinone of the invention and / or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and / or salt.

The present invention relates to oxazolidinone Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of an oxazolidinone of the invention and / or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and / or salt.

The present invention discloses an oligonucleotide which comprises a part or the entire sequence of the nucleotide sequence depicted in SEQ ID NO: 1, 2, 3 or 4, or a part or the entire sequence of a nucleotide sequence complementary to the nucleotide sequence, wherein the oligonucleotide is capable of hybridizing with the nucleotide sequence of Mycobacterium kansasii; a primer and a probe for use in the detection of Mycobacterium kansasii comprising the oligonucleotide; and a method for detecting Mycobacterium kansasii using the primer and / or probe.The method for detecting Mycobacterium kansasii enables the detection of M. kansasii more rapidly and with higher accuracy compared with a conventional bacterium identification method performed by culture examination on a bacterium. Further, the method can exclude any false positive result for the diagnosis and can also detect and diagnose M. kansasii with higher accuracy compared with a diagnosis method performed by PCR using a conventional primer and / or probe. Still further, the method can quantify a M. kansasii cell.

The invention discloses a construction method and application of a mycobacterium genetically engineered bacterium, belonging to the technical field of genetic engineering. In the present invention, after the recombinant plasmid is transformed into mycobacterium LY-1 cells, the sgRNA will recognize a specific region on the genome and guide the Cas9 protein to bind to the target site. Under the action of the protein, a double strand is formed at the target site Most of the cells die because of the broken gap: the homologous repair sequence introduced with the recombinant plasmid is integrated into the gap through double exchange under the action of recombinase, and the cells with successful gene homologous repair survive and form gene loss. Artificially designed genotypes such as living and exogenous gene insertions. The CRISPR-Cas9 system constructed by the present invention has a knockout efficiency of 60% for the same gene, which is more convenient and efficient than the existing mycobacterial gene editing methods.

The present invention relates to a composition and method for treating cancer in the urinary bladder. More particularly, the present invention relates to a composition comprising a Mycobacterium phlei (M. phlei) deoxyribonucleic acid (M-DNA)-M. phlei cell wall complex (MCC), wherein the M-DNA is preserved and complexed on the M. phlei cell wall, and a pharmaceutically acceptable carrier. The MCC composition inhibits proliferation of and induces apoptosis in the cancer cells in the urinary bladder of the animal.

Disclosed herein is 10-α / β-D-Arabinofuranosylundecenes of general Formula (II) or pharmaceutically acceptable salts thereof as anti-mycobacterial agents in vitro; (II) wherein R, R1 and R″ are as defined herein in the specification. The present invention also discloses a simple stereoselective synthesis 10-α / β-D-Arabinofuranosylundecenes of Formula (II) to target enzymes involved in the biosynthesis of cell wall of Mycobacterium and thus useful as inhibitors in the Mycobacterium tuberculosis drug development.

The present disclosure is generally directed to methods and systems for the rapid detection of mycobacteria in samples using lectin-conjugated silica coated magnetic nanoparticles (SMNPs). In this work, carbohydrates on the cell wall of the mycobacteria serve as binding sites for lectins conjugated on the surface of lectin-conjugated SMNPs. As the target species of mycobacteria bind to lectin-conjugated SMNPs, a precipitate forms, which can be magnetically separated from the bulk test solution to visually indicate the presence of the target species of mycobacteria. The present disclosure is utilized as an inexpensive and rapid point of care system in one embodiment. In another embodiment, the methods and systems are integrated into a lateral flow assay for rapid detection of the target species of mycobacteria. In yet another embodiment, the methods and systems are utilized to create a microfluidic detection device with increased sensitivity to mycobacteria in a sample.